Back to News

Categories: News | Published On: May 28, 2025 | Written by webadmin@biolojic.com |

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

Back to News
More News
  • Biolojic Design Appoints Neal Curran as Chief Business Officer
    Read More
  • Biolojic Design Joins Johnson & Johnson Innovation – JLABS
    Read More
BUSINESS AND MEDIA INQUIRIES

Micah Pearlman
micah@biolojic.com